Onexio Biosystems

Onexio Biosystems LLC develops technologies for high-throughput (96, 384 and 1536-well) co-culture and multi-culture applications. Traditional HTS screens typically utilize a single reporter cell type that lacks important confounding biology including drug metabolism, paracrine and endocrine cell:cell interactions. Screening results are therefore plagued by false-negatives and false-positives that stem from the oversimplified biology of mono-culture assays. Co-culture of a reporter cell assay with other cell types is viable solution to this problem, but traditional compartmentalized co-culture assays are not well suited for robotic HTS. A better solution would be to retrofit existing reporter assays in a technically simple manner that seamlessly integrates with existing robotic infrastructure (e.g. no new equipment required) and is also compatible with 384 and 1536 well HTS. Our first product, the microDUO fills this market need.